China Medical Sales Channel Report, 2006-2007
  • Mar/2007
  • Hard Copy
  • USD $800
  • Pages:50
  • Single User License
    (PDF Unprintable)       
  • USD $900
  • Code: DY002
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $1,800
  • Hard Copy + Single User License
  • USD $1,000

In the first three quarters of 2006, the total sales value of top seven medicine merchandises in China amounted to RMB 211.838 billion, up by 8.07% year-on-year, among which, the total sales value of drug reached RMB 156.805 billion, increased by 7.34% over the same period of 2005; total sales value of Chinese traditional patent medicine totaled RMB 37.205 billion, up by 10.06% compared a year earlier.

As for the major sales channels for drug, there are now following four forms: regional general agency, exclusive agency, multi-dealer agency and sales channels established by drug manufacturers. The sales terminals include hospitals at all levels, health centers/clinics and retail drugstores, etc.

Proportion of Sales Revenue by Drug Terminal, Jan-Nov 2006

At present, the profit margin of drug wholesalers in USA is very low, the average gross margin, expense ratio and net profit ratio are 4%, 2% and 1.6% respectively, but they can still make profits as a whole owing to the large scale on the average. Nevertheless, for Chinese drug circulation enterprises, the average gross margin is 8.21%, but the average expense ratio is rather high, reaching 7.65%, so the net profit margin is as low as 0.57%, all of which are also ascribed to enterprises lacking of scale effect plus poor management.

Profitability of Drug Wholesalers between China and USA

As the emerging medium and low-end drug markets, both rural drug market and urban community medical institutions can bring great opportunities for drug circulation enterprises. Since 2006, China has improved the subsidy standard for the farmers who participate in the new-type rural cooperative medical system, where the central finance has allotted RMB 20 per person per year against RMB 10 in 2005, the local finance has also increased the subsidy by RMB 10, and meanwhile, the personal charging standard of farmers still keeps unchanged at RMB 10. What's more, according to the plan, the test regions of new-type rural cooperative medical system will cover 40% of the counties (cities, districts) all over China in the year of 2006 and will reach 60% in the 2007. Moreover, it will be introduced to all around China in the year of 2008 and then will basically achieve the goal of covering the rural areas by 2010. And this indicates that the launch of the new-type rural cooperative medical system will bring a drug market potential of approximately RMB 45 billion in the next 5 years.

The supervisory and administrative departments of food & drug have established the so called Blacklist System for commercial bribery enterprise in April 2004, which can help to control the distribution of the prescription drug in China. The individual drug distributors with 70% of market shares were forced to retreat from this drug sales channel (hospitals). In order to succeed in the change for marketing mode of prescription drug from traditional brokerage sales to brand building that takes time and energy, the drug enterprises have to take the lead in launching new products by innovation so as to maintain stable profit margins. As a result, the drug enterprises advantageous in sales channels may first get out of the depression.

Based on the advantages and disadvantages of traditional sales channels, the report brings forward some suggestions for the drug makers, distributors as well as the sales terminals. Besides, it gives a research on the new-type drug sales channels and models such as cosmetic drugstore, medical e-commerce, self-established sales channel, and predicts the development trend of sales channels in pharmaceutical industry. Therefore, the report is of great reference value for enterprises that are engaging in or interested in drug production and sales as well as the related enterprises & organizations.

1. Overview
1.1 Sales Channel of Drug
1.2 Drug Producers and Operators
1.3 Supervision Organization and Management Laws & Regulations

2. Current Status of China Drug Sales Channel
2.1 Development History and Trend
2.1.1 Development History
2.1.2 Development Trend
2.2 Forms of Sales Channel
2.2.1 Regional General Agent
2.2.2 Exclusive Agency
2.2.3 Multi-dealers Agency
2.2.4 Direct Marketing by Drug Producer
2.3 Problems and Causes
2.3.1 Lack of Products and High-quality Services
2.3.2 Serious Problem Exist in Drug Distributors
2.3.3 Construction on Sales Terminals Should Be Strengthened
2.3.4 Severe Conflicts among Drug Sales Channels

3. Industry Chain of Drug Sales Channel
3.1 External Environments
3.1.1 Economic Environment
3.1.2 Politics and Laws
3.1.3 Social Culture
3.1.4 Market Competition
3.2 Internal Environment
3.2.1 Drug Producers
3.2.2 Drug Distributors
3.3.3 Drug Consumers
3.3.4 Drug Marketing Staff

4. Key Enterprises Involved in Drug Operation in China
4.1 China National Medicines Corporation Ltd
4.2 Shanghai Pharmaceutical Co., Ltd
4.3 Huadong Medicine Co., Ltd
4.4 Jinling Pharmaceutical Co., Ltd
4.5 Wuhan Jianmin Pharmaceutical Group Co., Ltd
4.6 Dalian Merro Pharmaceutical Co., Ltd
4.7 Zhejiang Int'l Group Co., Ltd

5. Suggestions and Market Opportunity of China Drug Sales Channel
5.1 Suggestions
5.1.1 Improvement of Drug Producers
5.1.2 Improvement of Drug Distributors
5.1.3 Improvement of Retail Terminals
5.1.4 Solutions to Problems related to Channels in the Bidding System
5.2 Market Opportunity
5.2.1 Rural Drug Sales Channels
5.2.2 Online Drug Sales
5.2.3 New Drug Sales Channels
Sketch Map of Drug Sales Channels
Operating Performance of China National Medicines Corporation Ltd, 2001-2006
Profitability of China National Medicines Corporation Ltd, 2001-2006
Operating Performance of Shanghai Pharmaceutical Co., Ltd, 2001-2006
Profitability of Shanghai Pharmaceutical Co., Ltd, 2001-2006
Operating Performance of Huadong Medicine Co,, Ltd, 2001-2006
Profitability of Huadong Medicine Co,, Ltd, 2001-2006
Operating Performance of Jinling Pharmaceutical Co., Ltd, 2001-2006
Profitability of Jinling Pharmaceutical Co., Ltd, 2001-2006
Operating Performance of Wuhan Jianmin Pharmaceutical Group Co., Ltd, 2001-2006
Profitability of Wuhan Jianmin Pharmaceutical Group Co., Ltd, 2001-2006
Operating Performance of Dalian Merro Pharmaceutical Co., Ltd, 2001-2006
Profitability of Dalian Merro Pharmaceutical Co., Ltd, 2001-2006
Operating Performance of Zhejiang Int'l Group Co., Ltd, 2001-2006
Profitability of Zhejiang Int'l Group Co., Ltd, 2001-2006
Development Trend of Cooperation between Upstream and Downstream Enterprises of Drug Marketing Channel
Enterprises with Business Volume over RMB 10 million at the 2nd National Pharmaceutical Product Trade Fair, 2006
Main Economic Benefit Indexes of Key Drug Sub-industries, 2006H1
Drug Purchase and Sales Value of Hospitals in China, 2003-2005
Distinct Difference of Consumer Behaviors between Prescription Drug and OTC

China Interventional Cardiovascular Device Industry Report,2014-2017

The prevalence of cardiovascular disease in China impacted by accelerated aging of population and changes in consumption concept, dietary habit, way of working and other lifestyles has been growing ye...

China PTCA Balloon Market Investment Report, 2014-2016

PTCA balloon, as a indispensable medical device in percutaneous coronary intervention (PCI), serves not only as a delivery system for stent, but also as a device for pre-/post-stent dilatations. There...

China Orthopedic Instrument Industry Report, 2014-2017

Benefiting from accelerated aging population and rising proportion of reimbursement for medical expenses, the Chinese orthopedic instrument market demand has been effectively released, with its scale ...

China Hospital Development and Investment Report, 2014-2017

China hospital industry has been developing quickly in recent years, thanks to the market demand stimulus and steady progress in health care reform. The number of Chinese hospitals grew at a CAGR of 6...

China Diagnostic Reagent Industry Report, 2013-2016

With the accelerated aging of the Chinese population, the increase of personal health expenditure as well as the improved medical care facilities and government health care system, China diagnostic re...

China Hemodialysis Equipment Import and Export Report, 2013-2016

Hemodialysis equipment is the most widely used treatment apparatus in blood purification, primarily targeting patients with acute or chronic renal failure.The Chinese hemodialysis equipment market sho...

Global and China Hemodialysis Industry Report, 2013-2016

Hemodialysis, also known as artificial kidney, is a type of blood purification technology, primarily applicable to the treatment of patients with rental failure. In 2013, the global number of patient...

China Portable Medical Equipment Industry Report, 2013-2016

With the synergy of favorable policies, improvement in living standards and healthcare awareness raising, China’s portable medical device industry has shown rapid development in recent years, with mar...

China Medical Informatization Industry Report,2013-2016

Under the impetus of multiple favorable policies and market demand, China's medical informatization industry has entered a rapid development stage in recent years. As of the first half of 2013, manage...

China Aged Care Industry Report, 2013-2016

Currently, China has entered the accelerated aging period. China’s population aged 65 and above reached 131.61 million in 2013, accounting for 9.7% of total population; and the proportion will rise to...

China Pharmaceutical Equipment Industry Report, 2013-2016

After decades of development, China has become a major producer of pharmaceutical equipment in the world. Since 2010, affected by the new GMP certification and other factors, the revenue and total pro...

China Dental Industry Report, 2013-2016

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental appliances (equipments and consumables), dental medical services, etc. with...

China Medical Monitor Industry Report, 2013-2015

In 2007-2011, the Chinese medical monitor market size rose from RMB1.16 billion to RMB3.08 billion at a CAGR of 27.8%. In 2012, the figure reached RMB3.86 billion, a year-on-year increase of 25.3%, of...

China Interventional Cardiovascular Device Industry Report, 2013-2015

With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning Commission of the People’s Republi...

China Diagnostic Reagent Industry Report, 2013-2015

Driven by huge population base, intensified aging and many favorable policies, China diagnostic reagent industry has been developing rapidly. In 2008-2012, the diagnostic reagent market size presented...

China Orthopedic Instrument Industry Report, 2013-2015

Benefiting from aging of population, consumption upgrade and policy support, China's orthopedic instrument industry has seen rapid development over the years, with total market size rising from 3.28 b...

China Ophthalmic Hospital Industry Report, 2012-2015

With the growing types of eye diseases and non-basic medical needs, China’s ophthalmic hospital industry has seen rapid development. In 2011, the number of ophthalmic hospitals in China reached 288, w...

China Chinese Patent Medicine Industry Report, 2012-2015

In recent years, China’s Chinese patent medicine industry has been running in good condition, with the revenue increasing from RMB 142 billion in 2008 to RMB 360 billion in 2012 at a CAGR of 26.2%. Ov...

2005-2014 All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号